Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betamethasone valerate + neomycin sulfate is a topical combination therapy developed by Vanan Pharma for the treatment of corticosteroid-responsive dermatoses complicated by secondary bacterial infections. Betamethasone valerate is a potent synthetic glucocorticoid that acts as a glucocorticoid receptor agonist, providing anti-inflammatory, antipruritic, and vasoconstrictive effects by modulating gene expression. Neomycin sulfate is an aminoglycoside antibiotic that provides broad-spectrum antibacterial activity by binding to the 30S ribosomal subunit of bacteria, thereby inhibiting protein synthesis. This combination is typically formulated as a cream for topical application to affected skin areas, addressing both the underlying inflammatory condition and the associated bacterial infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betamethasone valerate + neomycin sulfate.